SCHEMBL5136229

SCHEMBL5136229

C=CCOC(=O)CNC(=O)OC(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.50
TSHR P16473 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
GAA P10253 1/20 0.39
ALDH1A1 P00352 2/20 0.39
CA12 O43570 3/20 0.38
CA2 P00918 3/20 0.38
CA14 Q9ULX7 1/20 0.38
CA1 P00915 2/20 0.38
CA9 Q16790 2/20 0.38
CTSK P43235 1/20 0.36
EPHX2 P34913 1/20 0.35
EPHX1 P07099 1/20 0.35
MAPT P10636 2/20 0.34
HPGD P15428 1/20 0.34
CACNA1B Q00975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13471245 0.94 SMN1; SMN2 (0.46) SMN1; SMN2TSHRTDP1MAOAMAOB
SCHEMBL7154752 0.88 MAOA (0.47) SMN1; SMN2TSHRTDP1MAOAMAOB
SCHEMBL22175642 0.85 MAOA (0.55) SMN1; SMN2TSHRTDP1MAOAMAOB
SCHEMBL21738506 0.85 SMN1; SMN2 (0.47) SMN1; SMN2TSHRTDP1MAOAMAOB
SCHEMBL1631203 0.84 MAOA (0.44) SMN1; SMN2TSHRTDP1MAOAMAOB
SCHEMBL1276792 0.83 TDP1 (0.49) SMN1; SMN2TDP1MAOAMAOBMEN1
SCHEMBL8056145 0.82 TDP1 (0.43) SMN1; SMN2TSHRTDP1MAOAMAOB
SCHEMBL21416167 0.81 CTSK (0.45) SMN1; SMN2TSHRTDP1MAOAMAOB
SCHEMBL6823130 0.81 CA12 (0.41) SMN1; SMN2TSHRTDP1MAOAMAOB
SCHEMBL434612 0.81 CA12 (0.43) SMN1; SMN2TSHRTDP1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024151843-A1 TARGETED UNIVERSAL DELIVERY SYSTEM OF DON AND OTHER DRUGS THE JOHNS HOPKINS UNIVERSITY (US) 2024-07-18 WO disclosed
WO-2024151843-A1 TARGETED UNIVERSAL DELIVERY SYSTEM OF DON AND OTHER DRUGS THE JOHNS HOPKINS UNIVERSITY (US) 2024-07-18 WO disclosed
US-11389464-B2 Arginase inhibitors as therapeutics MARS, INCORPORATED (US) 2022-07-19 US disclosed
US-10377699-B2 Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue THE UNIVERSITY OF HONG KONG (CN) 2019-08-13 US disclosed
EP-1866347-B1 PROPYLENE POLYMER CATALYST DONOR COMPONENT INEOS TECH USA LLC (US) 2018-05-09 EP disclosed
US-20170190729-A1 POLYENE MACROLIDE DERIVATIVE SHIONOGI & CO., LTD. (JP) 2017-07-06 US disclosed
WO-2017007701-A1 ANTIVIRAL PHOSPHODIAMIDE COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2017-01-12 WO disclosed
US-20150126707-A1 DAPTOMYCIN ANALOGUES AND A METHOD FOR THE PREPARATION OF DAPTOMYCIN OR A DAPTOMYCIN ANALOGUE THE UNIVERSITY OF HONG KONG (CN) 2015-05-07 US disclosed
US-8288606-B2 Magnesium, titanium, and halogen; internal electron donor, ethyl N-Boc-sarcosine, ethyl N-propionyl sarcosine, ethyl N-Boc-pipercolinate, N-carbobenzyloxy-L-proline methyl ester; polymerize propylene and ethylene or alpha-olefin; internal modifier which does not contain a phthalate derivative INEOS USA LLC (US) 2012-10-16 US disclosed
US-20080125614-A1 Propylene polymer catalyst donor component INNOVENE USA (US) 2008-05-29 US disclosed
EP-1866347-A2 PROPYLENE POLYMER CATALYST DONOR COMPONENT INEOS USA LLC (US) 2007-12-19 EP disclosed
WO-2006110234-A2 PROPYLENE POLYMER CATALYST DONOR COMPONENT INEOS USA LLC (US) 2006-10-19 WO disclosed
WO-1991004268-A1 [N-(η-GLUTAMYL)GLYCYL]ALANINE DERIVATIVES SANDOZ LTD. (CH) 1991-04-04 WO disclosed
US-4970297-A CONTAINING ISOXAZOLE RING SYNTEX (U.S.A.) INC. (US) 1990-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125614-A1 Propylene polymer catalyst donor component RAD52, PGR, DRD2 SMN1; SMN2 2741/4885TSHR 341/4885TDP1 1259/4885
US-10377699-B2 Daptomycin analogues and a method for the preparation of daptomycin or a daptomycin analogue SCD, SCD5, FASN SMN1; SMN2 4047/4885TSHR 2347/4885TDP1 4270/4885
US-11389464-B2 Arginase inhibitors as therapeutics ARG1, ARG2, PRMT1 SMN1; SMN2 3461/4885TSHR 573/4885TDP1 1099/4885
US-20170190729-A1 POLYENE MACROLIDE DERIVATIVE ERG28, RPL23, RPL10 SMN1; SMN2 4749/4885TSHR 4491/4885TDP1 4057/4885
US-20150126707-A1 DAPTOMYCIN ANALOGUES AND A METHOD FOR THE PREPARATION OF DAPTOMYCIN OR A DAPTOMYCIN ANALOGUE SCD, SCD5, FASN SMN1; SMN2 3944/4885TSHR 2372/4885TDP1 4228/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.